Rosanne Dunn

Dr. Dunn is the scientific founder of HaemaLogiX and has over 20 years of experience in the fields of immunology, haematology, translational medicine and drug development. She was involved in the discovery of the lead therapeutic antibody KappaMab and in taking the antibody from the laboratory through to preclinical and clinical development.

Dr. Dunn heads the HaemaLogiX team in the development of the kappa myeloma antigen chimeric antigen receptor (KMA.CART) preclinical, translational studies and clinical development program. She is also responsible for the preclinical and translational studies of the company’s LambdaMab antibodies and bispecific antibody development.

​Dr Dunn is an author on the company’s patents and was awarded a Ph.D. in antibody engineering from the University of Technology, Sydney.